Skip to contentR
Revolution Medicines, Inc.
R
RVMDWRevolution Medicines, Inc. Q1 2026 · 10-Q
Revenue—
Net Income-$453.82M-$453.82MN/M vs Q1 2025 EPS Diluted-$2.29-$2.29N/M vs Q1 2025 Operating Income-$445,222,000N/M Operating Cash Flow-$354,165,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revolution Medicines, Inc. · CIK 1628171 · Engraved from SEC EDGAR
Free Cash Flowderived-$355,703,000N/M ended Mar 31, 2026 · filed May 6, 2026 · 36 d after period end